Table 5

 Rates of serious adverse events during the blinded and open label extension period of the ARMADA trial

Serious adverse eventEvents/100 patient-years
ARMADA blinded period*ARMADA total exposure†
*87 patient-years of total exposure; †886 patient-years of total exposure (as of 31 August 2004).
Serious infections2.302.03
    Urinary tract infections0.000.23
    Septic arthritis0.000.11
Demyelinating diseases0.000.11
SLE/lupus-like syndrome0.000.00
Congestive heart failure0.000.11